Reaching Others University at Buffalo - The State University of New York
Skip to Content
photo

Joseph Balthasar

School of Pharmacy and Pharmaceutical Sciences, Professor

Specialty/Research Focus

Development of drug targeting strategies to improve the selectivity of cancer chemotherapy and on the development of new immunotherapies for the treatment of humoral autoimmune diseases.

Abstracts and Proceedings

1.         Balthasar JP, A new method for estimating clearance form pre-steady state pharmacokinetic data. Sixth Japanese-American Conference on Pharmacokinetics and Biopharmaceutics, 1992.

2.         Balthasar JP and Fung H-L, The production, purification and characterization of high-affinity antibodies directed against methotrexate. Pharmaceutical Research 11(8): S-79, 1994.

3.         Balthasar JP and Fung H-L, Utilization of anti-drug antibodies for the optimization of intraperitoneal drug therapy: Illustration with digoxin. FASEB Journal 8(4): A99, 1994.

4.         Balthasar JP and Fung H-L, Optimization of intraperitoneal cancer chemotherapy with anti-drug antibodies: Pharmacokinetic rationale and experimental results. Pharmaceutical Research 12(9): S-3, 1995.

 5.        Fung H-L, Balthasar JP and Bauer JA, Pharmacokinetics and pharmacodynamics of organic nitrate tolerance. 3rd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology-JC , 1996.

6.         Bauer JA, Balthasar JP and Fung H-L, Rational PK/PD design of infusion regimens to overcome nitroglycerin tolerance development. Pharmaceutical Research 13(9): S-445, 1996.

7.         Balthasar JP and Scherrmann JM, Hybrid physiologic-compartmental model of digoxin and anti-digoxin Fab (ADF) disposition and interaction: Accuracy in predicting plasma concentration data from patients treated with ADF following intentional digoxin overdoses. Pharmaceutical Research 14(11): S-507, 1997.

8.         Balthasar JP, Alteration of vinorelbine pharmacokinetics in rats through the infusion of a lipid emulsion. AAPS PharmSci 1(4), 1999.

9.         Lobo ED and Balthasar JP, PK/PD modeling of methotrexate toxicity in mice. American Journal of Pharmaceutical Education 63: 71S, 1999.

10.        Balthasar JP, HPLC assay for quantification of vinorelbine in rat blood and plasma. AAPS PharmSci 1(4), 1999.

11.        Hansen RJ and Balthasar JP, Pharmacokinetics and platelet binding of 7E3, a murine anti-GPIIb-IIIa monoclonal antibody, in the rat. AAPS PharmSci 1(4), 1999.

12.        Hansen RJ and Balthasar JP, Pharmacokinetics and pharmacodynamics of a murine anti-platelet antibody, 7E3: A quantitative passive model of immune thrombocytopenia in the rat. AAPS PharmSci 1(4), 1999.

13.        Hansen RJ and Balthasar JP, Quantification of a murine monoclonal anti-platelet antibody, AP-3, in rat plasma using an enzyme-linked immunosorbent assay. AAPS PharmSci 1(4), 1999.

14.        Ludwig EA, Hossfeld MS, Balthasar JP and Brass C, Impact of pharmacist-adjusted initial antibiotic dosage. Pharmacotherapy 19(4): 540, 1999.

15.        Tayab ZR and Balthasar JP, An ELISA to quantify anti-methotrexate IgG in rat plasma. 22nd Annual Pharmacy Student Research Conference - Eastern States West Virginia University, 2000.

16.        Lobo ED and Balthasar JP, Prediction of agonistic and antagonistic effects of anti-methotrexate antibodies via computer simulation. AAPS PharmSci 2(4), 2000.

17.        Lobo ED and Balthasar JP, Application of a general time-dissociated pharmacokinetic-pharmacodynamic model to characterize methotrexate induced weight loss in mice. AAPS PharmSci 2(4), 2000.

18.        Hansen RJ and Balthasar JP, Effects of Pooled Human Immunoglobulin on Anti-Platelet Antibody Production and Platelet Binding, In Vitro. AAPS PharmSci 2(4), 2000.

19.        Hansen RJ and Balthasar JP, Pharmacokinetic /pharmacodynamic investigations into the effects of intravenous immunoglobulin in a rat model of immune thrombocytopenia. AAPS PharmSci 3(4), 2001.

20.        Lobo ED and Balthasar JP, Paradoxical effect of anti-methotrexate antibodies on methotrexate toxicity: Agonistic and antagonistic effects. AAPS PharmSci 3(4), 2001.

21.        Wang EQ, Balthasar JP and Fung HL, Pharmacodynamic modeling of in vivo nitroglycerin (NTG) tolerance in conscious rats: Effects of dose and dosage regimen. AAPS PharmSci 3(4), 2001.

22.        Lobo ED and Balthasar JP, Investigation of the efficacy of methotrexate chemotherapy of mice bearing sarcoma 180 and Erhlich ascites cells, following four equally toxic dosing protocols. AAPS PharmSci 4(4), 2002.

23.        Chen J and Balthasar JP, Determination of topotecan in mouse plasma by high-performance liquid chromatographic assay. AAPS PharmSci 4(4), 2002.

24.        Tayab ZR and Balthasar JP, Development and validation of an enzyme-linked immunosorbent assay for the quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. AAPS PharmSci 4(4), 2002.

25.        Tayab ZR and Balthasar JP, Application of high-dose monoclonal antibody therapy to saturate FcRn: Investigation of the dose-dependence of the pharmacokinetics of a monoclonal antibody in rats. AAPS PharmSci 4(4), 2002.

26.        Hansen RJ and Balthasar JP, Investigation of intravenous immunoglobulin effects on anti-platelet antibody disposition in wild-type and FcRn-deficient mice. AAPS PharmSci 4(4), 2002.

27.        Lobo ED and Balthasar JP, Utilization of anti-methotrexate Fab fragments to optimize i.p. methotrexate (MTX) chemotherapy: Dose escalation and enhancement of MTX efficacy in a mouse model of peritoneal cancer. AAPS PharmSci 4(4), 2002.

28.        Hansen RJ and Balthasar JP, Quantitative analysis of the inhibitory effects of intravenous immunoglobulin on anti-platelet antibody production, in vitro. AAPS PharmSci 4(4), 2002.

29.        Hansen RJ and Balthasar JP, Application of PK/PD modeling for the investigation of mechanisms of intravenous immunoglobulin action in a rat model of immune thrombocytopenia. AAPS PharmSci 4(4), 2002.

30.        Lobo ED and Balthasar JP, Pharmacokinetic modeling of chemotherapeutic effects: Application of a modified transduction model to characterize methotrexate effects on two cancer cell lines, in vitro. AAPS PharmSci 4(4), 2002.

31.        Jin F and Balthasar JP, Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. AAPS PharmSci 5(4), 2003.

32.        Chen J and Balthasar JP, Topotecan pharmacokinetics and toxicodynamics in mice. AAPS PharmSci 5(4), 2003.

33.        Deng R and Balthasar JP, Investigation of antibody-coated liposomes in vivo and in vitro as a therapy for immune thrombocytopenia. AAPS PharmSci 5(4), 2003.

34.        Deng R and Balthasar JP, Effects of antibody-coated liposome on 7E3-induced immune thrombocytopenia (ITP) in rats. AAPS Journal  6(4), 2004.

35.        Chen J and Balthasar JP, The effects of endogenous anti-topotecan antibodies on topotecan pharmacokinetics. AAPS Journal  6(4), 2004.

36.        Jin F, Getman K and Balthasar JP, Effects of a model FcRn inhibitor on the disposition of monoclonal antibodies in rats. AAPS Journal  6(4), 2004.

37.        Garg A and Balthasar JP, Application of a physiologically-based pharmacokinetic (PBPK) model to study the effects of FcRn and IVIG on IgG tissue disposition. AAPS Journal 6(4), 2004.

38.        Garg A and Balthasar JP, Investigation of the Tissue Disposition of 7E3, a Murine Monoclonal IgG1 Antibody, in Wild-Type and FcRn-Knockout Mice. AAPS Journal 7(S2), 2005.

39.        Deng R and Balthasar JP, Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. AAPS Journal 7(S2), 2005.

40.        Jin F, Getman K and Balthasar JP, Pharmacokinetic modeling of an anti-FcRn antibody and its effect on IgG disposition in rats. AAPS Journal 7(S2), 2005.

41.        Jin F and Balthasar JP, Development and in vitro evaluation of antibodies directed against the human neonatal Fc receptor (hFcRn). AAPS Journal 7(S2), 2005.

42.        Urva S, Lu Q, and Balthasar JP, Preclinical investigation of a new immune complex therapy for treatment of immune thrombocytopenic purpura (ITP). AAPS Journal 8(S2), 2006.

43.        Garg A and Balthasar JP, Application of a physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. AAPS Journal87(S2), 2006.

44.        Garg A and Balthasar JP, PBPK Analysis of the effects of IVIG and FcRn on IgG tissue disposition. AAPS National Biotechnology Meeting, San Diego, California, 2007.

45.        Shah D, Chen Y, Shin BS, Chen J, Balthasar JP, Simulations of the influence of antibody-ligand binding kinetics on the pharmacokinetics of "high-clearance" ligands. Pfizer/UB Alliance Annual Meeting, 2007